Equity Profile

PODD

Insulet Corporation

Health CareHealth Care Equipment$10.6B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Insulet Corporation (PODD) is a healthcare company that specializes in developing and manufacturing insulin delivery systems for people with diabetes. With a market cap of $10 billion, Insulet plays a crucial role in the health care equipment sector, particularly as diabetes management becomes increasingly important in public health.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability, and investors will be looking for strong earnings to support the company's growth narrative.

N/A

Revenue Growth

Revenue growth will indicate how well Insulet is expanding its market share and meeting customer demand.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PODD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+9.35%

Avg Stock Reaction

+1.69%

Last Quarter Recap

In Q1-2026, Insulet reported an EPS of $1.42, surpassing estimates by 24.78%. However, the stock fell 9.70% the following day, indicating market skepticism despite the earnings beat.

Management Promises & Guidance

Focus on expanding product offerings.
Commitment to improving customer service.
Plans to enhance manufacturing capabilities.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Insulet's upcoming earnings, given its recent performance. However, the stock's decline after positive earnings last quarter raises concerns about sustainability.

Bull Case

If Insulet continues to beat EPS estimates and shows strong revenue growth, it could reaffirm investor confidence and drive the stock higher.

Bear Case

Conversely, if the earnings report reveals disappointing revenue or slow product adoption, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to last quarter's surprise?

Given the significant EPS surprise last quarter, investors will closely watch if Insulet can maintain or improve its profitability.

What are the latest adoption rates for Insulet's products?

Understanding product adoption rates will provide insight into future revenue potential and market demand.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Insulet's ability to expand its product offerings and capture market share, especially in emerging markets.

Supporting Evidence

Recent trends indicate increased demand for diabetes management solutions, which Insulet is well-positioned to capitalize on.

The options market is pricing in a larger move than historical averages suggest, indicating potential for a positive surprise.

Key Risk

If product adoption rates exceed expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Insulet can sustain its growth trajectory amid increasing competition in the diabetes management space.

Bull Confirmed If

EPS growth of over 25% compared to last quarter would confirm the bull case.

Bear Confirmed If

An EPS below $1.20 could signal significant challenges ahead.

Pre-Earnings Positioning

Options Market

Implied Move

±21.46%

Historical Avg

±4.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±21.5% while PODD has averaged ±4.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

65.5%

Calls (14K)P/C Ratio: 1.72Puts (273K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insulet beats expectations, history suggests the stock could rise by an average of 1.90%, confirming a positive growth outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline of about 1.09%, reflecting ongoing concerns about the company's growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their expected impact on revenue.
2Any commentary on competition and market share dynamics.
3Insights into customer feedback and satisfaction levels.
4Guidance on future earnings and revenue expectations.
5Details on operational efficiencies and cost management strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability, and investors will be looking for strong earnings to support the company's growth narrative.

N/A

Revenue Growth

Revenue growth will indicate how well Insulet is expanding its market share and meeting customer demand.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PODD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+9.35%

Avg Stock Reaction

+1.69%

Last Quarter Recap

In Q1-2026, Insulet reported an EPS of $1.42, surpassing estimates by 24.78%. However, the stock fell 9.70% the following day, indicating market skepticism despite the earnings beat.

Management Promises & Guidance

Focus on expanding product offerings.
Commitment to improving customer service.
Plans to enhance manufacturing capabilities.

Expectations

Wall Street Expectations

Bull Case

If Insulet continues to beat EPS estimates and shows strong revenue growth, it could reaffirm investor confidence and drive the stock higher.

Bear Case

Conversely, if the earnings report reveals disappointing revenue or slow product adoption, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to last quarter's surprise?

Given the significant EPS surprise last quarter, investors will closely watch if Insulet can maintain or improve its profitability.

What are the latest adoption rates for Insulet's products?

Understanding product adoption rates will provide insight into future revenue potential and market demand.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Insulet's ability to expand its product offerings and capture market share, especially in emerging markets.

Supporting Evidence

Recent trends indicate increased demand for diabetes management solutions, which Insulet is well-positioned to capitalize on.

The options market is pricing in a larger move than historical averages suggest, indicating potential for a positive surprise.

Key Risk

If product adoption rates exceed expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Insulet can sustain its growth trajectory amid increasing competition in the diabetes management space.

Bull Confirmed If

EPS growth of over 25% compared to last quarter would confirm the bull case.

Bear Confirmed If

An EPS below $1.20 could signal significant challenges ahead.

Pre-Earnings Positioning

Options Market

Implied Move

±21.46%

Historical Avg

±4.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±21.5% while PODD has averaged ±4.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

65.5%

Calls (14K)P/C Ratio: 1.72Puts (273K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insulet beats expectations, history suggests the stock could rise by an average of 1.90%, confirming a positive growth outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline of about 1.09%, reflecting ongoing concerns about the company's growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their expected impact on revenue.
2Any commentary on competition and market share dynamics.
3Insights into customer feedback and satisfaction levels.
4Guidance on future earnings and revenue expectations.
5Details on operational efficiencies and cost management strategies.